NUVB
Nuvation Bio Inc.
NYSE · Healthcare · Biotechnology · US
$6.81
+0.59%Aug 6, 2026, 11:30 UTC
Nuvation Bio reported second quarter 2026 financial results, with total revenue of $31.7 million including $23.2 million in net product revenue for IBTROZI, and cash and marketable securities of $661.0 million as of June 30, 2026.
Aug 4, 2026, 12:00 UTC
Nuvation Bio announced it will present new subgroup analyses of pivotal Phase 2 TRUST-I and TRUST-II data for IBTROZI (taletrectinib) in advanced ROS1-positive non-small cell lung cancer at the WCLC and ESMO congresses in 2026.
Source:Jul 6, 2026, 21:09 UTC
Nuvation Bio Inc. announced the full exercise of the greenshoe option in its $287.5 million convertible senior notes offering, resulting in an additional $37.5 million aggregate principal amount of notes issued.
Source:Jun 30, 2026, 00:00 UTC
Nuvation Bio Inc. issued $250.0 million aggregate principal amount of 0.75% Convertible Senior Notes due 2032, with an option for underwriters to purchase an additional $37.5 million, generating approximately $241.2 million in net proceeds (approximately $277.6 million if the overallotment option is fully exercised).
Jun 26, 2026, 03:58 UTC
Nuvation Bio priced an upsized offering of $250.0 million of 0.75% Convertible Senior Notes due in 2032.
Source: